Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847728 · ClinicalTrials.gov registry record
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
A clinical trial of Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,189
- Enrollment target
- 20
- Study locations
NCT02847728: Completed study of Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.
NCT02847728 is a study of Lung Cancer and Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,189 participants, above the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02847728, a study of Lung Cancer and Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,189 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, and Spain. Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.
Conditions Studied
Study Locations (20)
Other
- Local Institution - 1103 - Innsbruck
- Local Institution - 1102 - Klagenfurt
- Local Institution - 1101 - Krems
Florida
- Local Institution - 1912 - Jacksonville
- Local Institution - 1907 - Lake City
Texas
- Local Institution - 1915 - El Paso
- Local Institution - 1905 - Fort Sam Houston
New South Wales
- Local Institution - 1001 - Lismore
- Local Institution - 1002 - Wagga Wagga
Victoria
- Local Institution - 1006 - Franskton
- Local Institution - 1003 - Wodonga
California
- Local Institution - 1909 - Palm Springs
Illinois
- Local Institution - 1901 - Park Ridge
Louisiana
- Local Institution - 1910 - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,189 participants |
| Start Date | 2016-07-28 |
| Est. Completion | 2024-03-31 |
What the finished NCT02847728 record still lists
NCT02847728 is an observational study that tracks outcomes without assigning an intervention. Its 1,189 participants enrollment target places it among the larger protocols in the corpus, above the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target (27% higher).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02847728 names 20 study sites across 14 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT02847728 about?
NCT02847728 is a clinical study titled "Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice". This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria...
What is the current status of trial NCT02847728?
This trial is currently completed. The enrollment target is 1,189 participants. The study started on 2016-07-28. Estimated completion is 2024-03-31.
What conditions does trial NCT02847728 study?
This clinical trial studies the following conditions: Lung Cancer, Melanoma.
Who is sponsoring clinical trial NCT02847728?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02847728 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02847728's enrollment target sits among peer trials
1,189 42nd of 409 higher than 368 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI